A prospective surveillance study in haemophilia B patients following a population switch to recombinant factor IX (nonacog gamma)
Évemie Dubé(Institut National de la Recherche Scientifique), Georges‐Étienne Rivard(Centre Hospitalier Universitaire Sainte-Justine), Arnaud Bonnefoy(Centre Hospitalier Universitaire Sainte-Justine), Jean‐François Castilloux(Centre Hospitalier Universitaire de Sherbrooke), Jean St‐Louis(Hôpital Maisonneuve-Rosemont), Catherine Vézina(McGill University Health Centre), Christine Demers(Centre hospitalier universitaire de Québec), Margaret R. Warner(Eli Lilly (United States)), Christine Sabapathy, Stéphanie Cloutier(Centre hospitalier universitaire de Québec), Julie Gauthier(Centre Hospitalier Universitaire Sainte-Justine), Clémence Merlen(Centre Hospitalier Universitaire Sainte-Justine)
Cited by 0
Related Papers
Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: A Gradient of Severity in Cognitive Impairments
|PLoS Genetics|2014|672
Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial
|The Lancet|2013|522
Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial
|Arthritis & Rheumatism|2009|497
Increased exonic de novo mutation rate in individuals with schizophrenia
|Nature Genetics|2011|448
De novo mutations in the gene encoding the synaptic scaffolding protein <i>SHANK3</i> in patients ascertained for schizophrenia
|Proceedings of the National Academy of Sciences|2010|380